New drug combo aims to stop head and neck cancer recurrence
Disease control
Ongoing
This study tests whether adding lenvatinib to pembrolizumab (immunotherapy) after standard chemoradiation can help prevent head and neck cancer from coming back. About 50 adults with advanced, PD-L1 positive cancer will receive either the combination or pembrolizumab alone as mai…
Phase: PHASE2 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Apr 29, 2026 03:25 UTC